Skip to main content
Caplight Logo









Etcembly

Etcembly

Private
DidcotHealthcare & Life Scienceshttps://www.etcembly.io/

Last Round

Series A

Extension

Dec 8, 2023

Est. Valuation

$29.9M

Total Funding Raised

$12.67M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Etcembly is a biotechnology company that utilizes a proprietary generative AI platform, EMLy™, to discover and engineer T-cell receptor (TCR) immunotherapies for cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, ML Platforms, Precision Medicine

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Revenue Share

AI Layer

Application

Keywords

TCR immunotherapyAI drug discoverygenerative AITCR discoveryTCR engineeringtechbioimmune engineeringgenerative biologyT-cell therapyin silico discoveryoncology therapeuticsbispecific T-cell engagersautoimmunity therapeuticsAI copilotin silico safety assessment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Etcembly Comparables

Compare Etcembly with similar companies based on industry and business-model similarity.

Etcembly comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Exogene
87%
Engimmune Therapeutics
83%
T-Cypher Bio
77%

Etcembly Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionDec 8, 2023
Series ADec 14, 2022
SeedApr 23, 2021

Key People

Founding team and executive leadership

Michelle Teng

Chief Executive Officer

Executive Team

Beckie Bown

Chief Financial Officer

Executive Team

Etcembly Investors

Notable investors and investment history

Etcembly investors
InvestorRounds
iGlobe PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 178% MoM, reaching 4.4K.

  • Mar 18, 2026

    Collaboration with Avigen Ltd. has been a resounding success.

Etcembly Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Etcembly Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Etcembly's valuation, stock price, and market status.

Firmographic Details

HeadquartersDidcot
Employee Range24
Year Founded2020
Last FundingDec 8, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?